Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond

Martin Wermke

National Center for Tumor Diseases–University Cancer Center Early Clinical Trial Unit, Technische Universität Dresden, Dresden, Germany

Valentina Gambardella

Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

Yasutoshi Kuboki

Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan

Enriqueta Felip

Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona

Miguel F. Sanmamed

Olatunji B. Alese

Winship Cancer Institute of Emory University, Atlanta, GA

Cyrus M. Sayehli

Martin Wermke, MD, TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; Valentina Gambardella, MD, PhD, Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; Yasutoshi Kuboki, MD, PhD, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan; Enriqueta Felip, MD, PhD, Department of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Miguel F. Sanmamed, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Olatunji B. Alese, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Cyrus M. Sayehli, MD, Interdisciplinary Study Center with ECTU, Medical Clinic and Polyclinic II of the University Hospital, Würzburg, Germany; Edurne Arriola, MD, PhD, Department of Medical Oncology, Hospital del Mar-CIBERONC (Centro de Inves...

Edurne Arriola

Hospital del Mar, Barcelona, Spain

Jürgen Wolf

Liza C. Villaruz

UPMC Hillman Cancer Center, Pittsburgh, PA

Julia Bertulis

Martin Wermke, MD, TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; Valentina Gambardella, MD, PhD, Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; Yasutoshi Kuboki, MD, PhD, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan; Enriqueta Felip, MD, PhD, Department of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Miguel F. Sanmamed, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Olatunji B. Alese, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Cyrus M. Sayehli, MD, Interdisciplinary Study Center with ECTU, Medical Clinic and Polyclinic II of the University Hospital, Würzburg, Germany; Edurne Arriola, MD, PhD, Department of Medical Oncology, Hospital del Mar-CIBERONC (Centro de Inves...

Matus Studeny

Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany

Mohamed Bouzaggou

Boehringer Ingelheim France S.A.S., Reims, France

Xiaoyan Fang

Daniel Morgensztern

Department of Medicine, Washington University School of Medicine, St. Louis